Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Neurobiol Aging ; 49: 165-182, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27815990

RESUMEN

Beta amyloid (Aß) is well accepted to play a central role in the pathogenesis of Alzheimer's disease (AD). The present work evaluated the therapeutic effects of low-level laser irradiation (LLI) on Aß-induced neurotoxicity in rat hippocampus. Aß 1-42 was injected bilaterally to the hippocampus CA1 region of adult male rats, and 2-minute daily LLI treatment was applied transcranially after Aß injection for 5 consecutive days. LLI treatment suppressed Aß-induced hippocampal neurodegeneration and long-term spatial and recognition memory impairments. Molecular studies revealed that LLI treatment: (1) restored mitochondrial dynamics, by altering fission and fusion protein levels thereby suppressing Aß-induced extensive fragmentation; (2) suppressed Aß-induced collapse of mitochondrial membrane potential; (3) reduced oxidized mitochondrial DNA and excessive mitophagy; (4) facilitated mitochondrial homeostasis via modulation of the Bcl-2-associated X protein/B-cell lymphoma 2 ratio and of mitochondrial antioxidant expression; (5) promoted cytochrome c oxidase activity and adenosine triphosphate synthesis; (6) suppressed Aß-induced glucose-6-phosphate dehydrogenase and nicotinamide adenine dinucleotide phosphate oxidase activity; (7) enhanced the total antioxidant capacity of hippocampal CA1 neurons, whereas reduced the oxidative damage; and (8) suppressed Aß-induced reactive gliosis, inflammation, and tau hyperphosphorylation. Although development of AD treatments has focused on reducing cerebral Aß levels, by the time the clinical diagnosis of AD or mild cognitive impairment is made, the brain is likely to have already been exposed to years of elevated Aß levels with dire consequences for multiple cellular pathways. By alleviating a broad spectrum of Aß-induced pathology that includes mitochondrial dysfunction, oxidative stress, neuroinflammation, neuronal apoptosis, and tau pathology, LLI could represent a new promising therapeutic strategy for AD.


Asunto(s)
Enfermedad de Alzheimer/etiología , Enfermedad de Alzheimer/radioterapia , Péptidos beta-Amiloides/metabolismo , Péptidos beta-Amiloides/toxicidad , Región CA1 Hipocampal/metabolismo , Terapia por Luz de Baja Intensidad , Dinámicas Mitocondriales , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/toxicidad , Enfermedad de Alzheimer/psicología , Animales , Apoptosis , Región CA1 Hipocampal/patología , Inflamación , Láseres de Semiconductores/uso terapéutico , Terapia por Luz de Baja Intensidad/métodos , Masculino , Neuronas/patología , Estrés Oxidativo , Ratas Sprague-Dawley , Reconocimiento en Psicología , Memoria Espacial , Tauopatías/etiología , Tauopatías/radioterapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA